BioMarin to Host a Research and Development Day on December 8th
NOVATO, Calif., Nov. 17, 2011 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons Hotel in New York City. Members of BioMarin’s management team and industry experts will provide an update on the company’s product portfolio and advancements in the research and development pipeline.
Dial-in information Toll-free number: (877) 643-7155 International number: (914) 495-8552 Conference ID #: 28775391 Replay information Toll-free number: (855) 859-2056 International number: (404) 537-3406 Conference ID #: 28775391
Interested parties may access a live audio webcast and slides of the presentation via the investor section of the BioMarin website, http://www.BMRN.com.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include NaglazymeÃ‚® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; AldurazymeÃ‚® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KuvanÃ‚® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.
BioMarinÃ‚®, NaglazymeÃ‚®, KuvanÃ‚® and Firdapse(TM) are registered trademarks of BioMarin Pharmaceutical Inc.
AldurazymeÃ‚® is a registered trademark of BioMarin/Genzyme LLC.
Contact: Investors Media Eugenia Shen Bob Purcell BioMarin Pharmaceutical BioMarin Pharmaceutical Inc. Inc. (415) 506-6570 (415) 506-3267
SOURCE BioMarin Pharmaceutical Inc.